EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Chromatin as an old and new anticancer target

Jacques Neefjes, Katerina Gurova, Jay Sarthy, Gábor Szabó, Steven Henikoff

Trends in Cancer · 2024-08 · 10 (8) · 696-707

DOI: 10.1016/j.trecan.2024.05.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2024-08. Verfasst von Jacques Neefjes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Chemical Biology and Oncode Institute, LUMC, Einthovenweg 20, 2333, ZC, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Chromatin, Neoplasms, DNA Damage, Antineoplastic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Howard Hughes Medical Institute, NCI NIH HHS, Nemzeti Kutatási Fejlesztési és Innovációs Hivatal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent genome-wide analyses identified chromatin modifiers as one of the most frequently mutated classes of genes across all cancers. However, chemotherapies developed for cancers involving DNA damage remain the standard of care for chromatin-deranged malignancies. In this review we address this conundrum by establishing the concept of 'chromatin damage': the non-genetic damage to protein-DNA interactions induced by certain small molecules. We highlight anthracyclines, a class of chemotherapeutic agents ubiquitously applied in oncology, as an example of overlooked chromatin-targeting agents. We discuss our current understanding of this phenomenon and explore emerging chromatin-damaging agents as a basis for further studies to maximize their impact in modern cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChromatinNeoplasmsDNA DamageAntineoplastic AgentsHumansMolecular Targeted TherapyAnthracyclinesAnimals

Stichwörter der Autor:innen

DNA damageanthracyclinescancerchromatin damagecuraxin

Substanzen

ChromatinAntineoplastic AgentsAnthracyclines

Autor:innen und Institutionen

  • Department of Cell and Chemical Biology and Oncode Institute, LUMC, Einthovenweg 20, 2333, ZC, Leiden, The Netherlands.
  • Department of Cell Stress Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. Electronic address: katerina.gurova@toswellpark.org.
  • Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Research Institute, 1920 Terry Ave, Seattle, WA 98109, USA.
  • Faculty of Medicine, Department of Biophysics and Cell Biology, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary.
  • Basic Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA 98109, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

Förderung

  • Howard Hughes Medical Institute
  • NCI NIH HHS
  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
  • National Institutes of Health
  • National Cancer Institute
  • National Research Development and Innovation Office
  • Oncode Institute
  • Burroughs Wellcome Fund

Zitieren

APA

Neefjes, J., Gurova, K., Sarthy, J., Szabó, G., & Henikoff, S. (2024). Chromatin as an old and new anticancer target. Trends in Cancer, 10(8), 696-707. https://doi.org/10.1016/j.trecan.2024.05.005

Vancouver

Neefjes J, Gurova K, Sarthy J, Szabó G, Henikoff S. Chromatin as an old and new anticancer target. Trends in Cancer. 2024;10(8):696-707. doi:10.1016/j.trecan.2024.05.005

BibTeX
@article{Neefjes2024,
  author = {Neefjes, Jacques and Gurova, Katerina and Sarthy, Jay and Szabó, Gábor and Henikoff, Steven},
  title = {Chromatin as an old and new anticancer target},
  journal = {Trends in Cancer},
  year = {2024},
  volume = {10},
  number = {8},
  pages = {696--707},
  doi = {10.1016/j.trecan.2024.05.005}
}
Kostenlos starten →